Eisai and Biogen move to bring IV maintenance dosing for Leqembi to the US
As Eli Lilly’s plans for its Alzheimer’s medication donanemab get delayed, Eisai has submitted a supplemental Biologics License Application (sBLA)…
drug development
-
-
Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Soon after GSK gained traction with a US Food and Drug Administration (FDA) fast track designation for its investigational treatment…
-
J&J reportedly eyeing Shockwave Medical for takeover
Johnson & Johnson (J&J) is allegedly looking to strengthen its presence in the cardiovascular device market with the acquisition of…
-
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
Amneal Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for…
-
IGC Pharma heads towards a Phase I study for Alzheimer’s disease
With positive preclinical data for its Alzheimer’s disease drug candidate TGR-63, IGC Pharma has announced that it plans to advance…
-
AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials
AmyriAD Therapeutics is looking to evaluate its lead Alzheimer’s disease small molecule candidate AD-101 in three upcoming Phase III studies,…
-
Sellas presses ahead with fast track designation for lymphoma
The US Food and Drug Administration (FDA) has granted a fast track designation to Sellas Life Sciences Group’s SLS009 for…
-
Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug
Allyx Therapeutics is planning a Phase II study to demonstrate proof of concept in Alzheimer’s disease with its lead drug…
-
EC expands Takeda’s Adcetris label for advanced Hodgkin lymphoma treatment
The European Commission (EC) has approved Seagen and Takeda Pharmaceuticals’ Adcetris (brentuximab vedotin)/chemotherapy combination as a first-line treatment for patients…
-
A New Chlamydia Vaccine on the Horizon
Sexually transmitted diseases (STDs) such as hepatitis B, chlamydia, syphilis, and gonorrhea are currently on the rise in many countries…
